High-throughput solutions powering academic and translational studies.
End-to-end tools for advanced biomarker discovery and development.
Scalable sequencing built for precision diagnostics and real-world deployment.
Directly detect native methylation—no bisulfite or PCR required.
Increase throughput and read quality, with proprietary protocols.
Profile methylation and structural variants from a single unified assay.
Built for multiplexing, cohort studies, and diagnostic-ready workflows.
Leverage our MethylSeqR tools and expert team for end-to-end support.
Tailor coverage depth and protocols to meet your research objectives.
Built on Oxford Nanopore technology, Wasatch BioLabs’ targeted platform eliminates amplification and bisulfite conversion, enabling streamlined, dual-mode profiling of genomic and epigenomic data. Target up to 50 genes, promoter regions, or methylation hot spots with flexible panel design.
Our platform delivers the depth and precision to confidently detect germline and somatic variants, rare frequency alleles, and methylation changes—providing comprehensive coverage across even the most biologically complex regions.
The native sequencing approach captures full-length, unmodified DNA molecules—enabling simultaneous detection of CpG, CHG, and CHH methylation, structural variants, and phasing of germline and somatic mutations without the bias introduced by PCR or bisulfite conversion.
Built for high-throughput applications, our platform supports flexible multiplexing and streamlined workflows, making it a cost-effective solution for large cohort studies, population-scale research, and clinical assay deployment.
Our platform delivers the depth and precision to confidently detect germline and somatic variants, rare frequency alleles, and methylation changes—providing comprehensive coverage across even the most biologically complex regions.
The native sequencing approach captures full-length, unmodified DNA molecules—enabling simultaneous detection of CpG, CHG, and CHH methylation, structural variants, and phasing of germline and somatic mutations without the bias introduced by PCR or bisulfite conversion.
Built for high-throughput applications, our platform supports flexible multiplexing and streamlined workflows, making it a cost-effective solution for large cohort studies, population-scale research, and clinical assay deployment.
.gif)
Wasatch BioLabs is the first full-scale clinical lab dedicated to Oxford Nanopore sequencing, offering proprietary platforms like dWMS and standard ONT services for flexible research support.
